-
1 Comment
Shandong Buchang Pharmaceuticals Co., Ltd is currently in a long term downtrend where the price is trading 6.2% below its 200 day moving average.
From a valuation standpoint, the stock is 82.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.7.
Shandong Buchang Pharmaceuticals Co., Ltd's total revenue rose by 9.7% to $4B since the same quarter in the previous year.
Its net income has dropped by 10.2% to $494M since the same quarter in the previous year.
Finally, its free cash flow grew by 172.3% to $443M since the same quarter in the previous year.
Based on the above factors, Shandong Buchang Pharmaceuticals Co., Ltd gets an overall score of 3/5.
| Exchange | SHG |
|---|---|
| CurrencyCode | CNY |
| ISIN | CNE100002FV6 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Target Price | None |
|---|---|
| Market Cap | 17B |
| PE Ratio | None |
| Beta | 0.59 |
| Dividend Yield | None |
Shandong Buchang Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of medicines in China. The company offers medicines to treat cardiac and cerebral vascular, urinary and digestive, respiratory, gynecological, and other diseases, as well as diabetes. Shandong Buchang Pharmaceuticals Co., Ltd. was founded in 1993 and is based in Heze, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 603858.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
